Navigation Links
Genetic Testing Explodes after Supreme Court Patent Decision
Date:8/20/2013

NEW YORK, Aug. 20, 2013 /PRNewswire-iReach/ -- Within weeks of the Supreme Court's historic decision declaring that human genes cannot be patented, two scientists have started a company that will democratize the human genome and give people direct access to their own genetic information – which can have an immediate impact on their health and well being. The court's decision spurred the two scientists, Christopher Mason, PhD, of Weill Cornell Medical College, and Jeffrey Rosenfeld, PhD, of Rutgers Medical School, to form Genome Liberty and begin offering immediate, personalized genetic testing directly to the public – although the results should used in concert with a doctor. 

(Photo:  http://photos.prnewswire.com/prnh/20130820/MN65902)

"The Supreme Court's decision opened an era of genomic liberty, allowing people to look at the DNA for all of their genes – which had been hidden behind patent walls for companies that had a monopoly on such testing," Mason said. "Our next-generation sequencing technology allows individuals to be proactive in understanding how their genome can affect their health decisions."

Previously, individuals had to rely on their doctors to understand their health and to make proper medical decisions for them. As scientists and doctors have found the molecular basis for disease and drug response, it has become increasingly clear that a "one-size-fits-all" framework for medicine is not in patients' best interest.

"Genome Liberty fills an important void in our current medical system," Rosenfeld said. "For example, there are clear genetic markers for many medications that will determine whether a person will respond properly or may have extreme side-effects, including estrogen, codeine, Plavix, Nexium, Prilosec, Zocor, Dilantin, Coumadin, Haloperidol, Abilify, and Celexa.  Such tests are very rarely performed before a drug is prescribed, but they offer distinct advantages.  They overcome most doctors' insufficient understanding of, and even fear of, genetics and genetic testing." 

Genome Liberty will work directly with consumers as well as doctors to offer a Gene-Drug Interaction Test. Here is how the test works:

  • A customer (1) orders the test on the Genome Liberty website; (2) receives a saliva-collection kit; (3) provides a saliva sample; and (4) mails the sample to Genome Liberty's certified medical lab, which extracts the DNA and tests it for the genetic variants corresponding to drug responses.
  • Customers receive a full report within two weeks to bring to their physician, outlining the medications that are recommended and discouraged, based upon an individual's specific genetic profile.

The test costs $99, provides information for a lifetime, and covers dozens of frequently prescribed drugs. It also looks for a condition known as Factor V Leiden that can cause dangerous blood clots when women who have this condition take estrogen, either for birth-control or hormone replacement.  Many of these tests are encouraged by the FDA on the drug label, but they are not widely requested.

"The test provides only immediately useful information," Mason said.  "Many people are wary of having a genetic test performed because they do not want results that will scare them.  Some people do not want to be told that they are at high risk for diseases that are currently untreatable. Genome Liberty's primary focus is on actionable genetic information to help people make smart medical choices."

Genome Liberty's co-founders are established leaders in genetics and the understanding the human genome. Dr. Christopher Mason is a faculty member of the Weill Cornell Medical School and was a witness for the successful plaintiffs in the Supreme Court case.  Dr. Jeffrey Rosenfeld is a faculty member at the Rutgers New Jersey Medical School where his research focuses on human genome variation. He is also a research associate at the American Museum of Natural History.

To learn more about Genome Liberty's mission, go to www.genomeliberty.com or to support their crowdfunding campaign, go to http://www.rockethub.com/29313.

Media Contact: Jeffrey Rosenfeld, Genome Liberty, 917-664-8374, jeff@genomeliberty.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Genome Liberty
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. BellBrook Labs Launches Second Generation Transcreener EPIGEN Methyltransferase Assay to Acclerate Epigenetic Drug Discovery
2. Epigenetic and MicroRNA Biomarkers 2013 Market Report
3. Population Genetics Assigns Asymmetric Adaptor Library Construction Patent To New England Biolabs
4. Cytogenetics - Technologies, Markets and Companies - 2013
5. Genetic Engineering: A New Use for Algae in Biofuel Production
6. Signal Genetics Announces Publication of BreastPRS™ Validation Study with Weill Cornell Medical College, New York
7. Signal Genetics LLC Announces Update to MyPRS™ Gene Expression Profiling Assay for Multiple Myeloma
8. BellBrook Labs and Tecan Offer Webinar on Screening Epigenetic Targets
9. Todays Technical View: Elan Corp., Amarin, Seattle Genetics, and Cubist Pharma
10. RiboMed and Austrian Institute of Technology Partner on Epigenetic Tests for Early Lung Cancer Detection, Sub-typing and Drug Response
11. Cellular Dynamics International Expands MyCell Products Line with Disease Models, Genetic Engineering Patents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of 8.5 ... end machines that use the more unconventional z-dimension of 20mm. Z-dimension or ... the cuvette holder. , FireflySci has developed several Agilent flow cell product lines ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
Breaking Biology Technology:
(Date:4/19/2016)... , UAE, April 20, 2016 ... implemented as a compact web-based "all-in-one" system solution for ... biometric fingerprint reader or the door interface with integration ... modern access control systems. The minimal dimensions of the ... readers into the building installations offer considerable freedom of ...
(Date:4/13/2016)... -- IMPOWER physicians supporting Medicaid patients in Central ... in telehealth thanks to a new partnership with higi. ... patients can routinely track key health measurements, such as ... when they opt in, share them with IMPOWER clinicians ... retail location at no cost. By leveraging this data, ...
(Date:3/23/2016)... 2016 Einzigartige ... und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler Kommunikationsdienste, ... SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie einzusetzen. ... Möglichkeit angeboten, im Rahmen mobiler Apps neben ...
Breaking Biology News(10 mins):